PRODUCT INFORMATION



S63845

Item No. 21131

CAS Registry No.:	1799633-27-4	
Formal Name:	α(R)-[[(5S)-5-[3-chloro-2-methyl-4-	CF ₃
	[2-(4-methyl-1-piperazinyl)ethoxy]	N
	phenyl]-6-(5-fluoro-2-furanyl)	
	thieno[2,3-d]pyrimidin-4-yl]oxy]-2-[[1-	
	(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]	
	methoxy]-benzenepropanoic acid	
MF:	$C_{39}H_{37}CIF_4N_6O_6S$	
	829.3	но (/)
FW:		$\gamma \circ \gamma = \langle$
Purity:	≥98%	0 / \
UV/Vis.:	λ _{max} : 324 nm	N
Supplied as:	A crystalline solid	
Storage:	-20°C	N ^S O ^F
Stability:	≥4 years	
In farmer the manufacture destination of the second state of the s		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

S63845 is supplied as a crystalline solid. A stock solution may be made by dissolving the S63845 in the solvent of choice, which should be purged with an inert gas. S63845 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of S63845 in these solvents is approximately 30 mg/ml.

S63845 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, S63845 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. S63845 has a solubility of approximately 0.125 mg/ml in a 1:7 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

S63845 is an inhibitor of myeloid cell leukemia 1 (Mcl-1; K_i = 0.19 nM), a pro-survival protein that is overexpressed in many cancers.¹ It induces cell death in multiple myeloma, leukemia, and lymphoma cell lines (IC_{50} = <0.1-282 nM) via mitochondrial apoptosis. S63845 acts synergistically with trametinib (Item No. 16292), lapatinib (Item No. 11493), PLX4032 (Item No. 10618), and erlotinib (Item No. 10483) to reduce proliferation of SK-MEL-2, BT474, A2058, and PC9 cells, respectively. S63845 (6.25-25 mg/kg) reduces tumor volume in an MV4-11 acute myeloid leukemia mouse xenograft model in a dose-dependent manner.

Reference

1. Kotschy, A., Szlavik, Z., Murray, J., et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538(7626), 477-482 (2016).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/26/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM